Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose
Status:
Completed
Trial end date:
2017-01-30
Target enrollment:
Participant gender:
Summary
This is a single-centre, open-label, non-randomized clinical trial designed to monitor the
occurrence of adverse events associated with [F-18]-FDG Injection manufactured by the Fedoruk
Centre. [F-18]-FDG Injection used in this clinical trial will be identical to commercial
[F-18]-FDG that is already used at Royal University Hospital (RUH).
Phase:
Phase 4
Details
Lead Sponsor:
University of Saskatchewan
Collaborators:
Saskatoon Health Region Sylvia Fedoruk Canadian Centre for Nuclear Innovation